Changing epidemiology of tardive dyskinesia: an overview

doi:10.1176/ajp.138.3.297

Cited by 101 publications

(3 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The allele frequencies found in our sample were consistent with those reported previously for European Caucasians (Sachse et al, 1997). The prevalence of TD in our sample is 19% (13/70) which is also consistent with other studies (Jeste and Wyatt, 1981; Kane and Smith, 1982). …”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

Association of tardive dyskinesia with variation in CYP2D6: Is there a role for active metabolites?

et al. 2014

View full text Add to dashboard Cite

Background The aim of this study was to examine whether there was an association between tardive dyskinesia (TD) and number of functional CYP2D6 genes. Methods A Caucasian sample of 70 patients was recruited in 1996–1997 from South London and Maudsley National Health Service (NHS) Foundation Trust, UK. Subjects had a DSM-IIIR diagnosis of schizophrenia and were treated with typical antipsychotics at doses equivalent to at least 100 mg chlorpromazine daily for at least 12 months prior to assessment. All patients were genotyped for CYP2D6 alleles*3–5, *41, and for amplifications of the gene. Results There were 13 patients with TD. The mean (standard deviation (SD)) years of duration of antipsychotic treatment in TD-positive was 15.8 (7.9) vs TD-negative 11.1 (7.4) (p=0.04). Increased odds of experiencing TD were associated with increased ability to metabolize CYP2D6, as measured by genotypic category (odds ratio (OR)=4.2), increasing duration in treatment (OR=1.0), and having drug-induced Parkinsonism (OR=9.7). Discussion We found a significant association between CYP2D6 genotypic category and TD with the direction of effect being an increase in the number of functional CYP2D6 genes being associated with an increased risk of TD. This is the first study to examine the association between TD and CYP2D6 in Caucasians with this number of genotypic categories. In the future, metabolomics may be utilized in the discovery of biomarkers and novel drug targets.

show abstract

Section: Discussionsupporting

confidence: 93%

“…The prevalence of TD from antipsychotic treatment TD is approximately 20% (Kane and Smith, 1982). Other studies have shown point-prevalence of 5–45% in psychiatric inpatients and 30% among psychiatric outpatients (Jeste and Wyatt, 1981). …”

Section: Introductionmentioning

confidence: 97%

Association of tardive dyskinesia with variation in CYP2D6: Is there a role for active metabolites?

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Spontaneous dyskinesias, unrelated to neurological conditions, are also known to occur in patients with mental illness. [ 9 ] However, the temporal association of the onset of dyskinesia with antipsychotic administration inclines us to think otherwise. For the same reason, and because of the absence of new stressors, and typical site and character of abnormal movements, dissociative symptoms were ruled out.…”

Section: Discussionmentioning

confidence: 99%

Acute-onset Orofacial Dyskinesia with a Single Low Dose of Oral Flupentixol: A Case Report

Gupta¹,

Gupta²,

Balhara³

2018

Indian Journal of Psychological Medicine

View full text Add to dashboard Cite

Tardive dyskinesia are known to occur commonly among patients receiving neuroleptic drugs for prolonged periods. But, few reports of acute onset dyskinesia have also been reported in the literature. This report highlights one such case where the patient had dyskinetic movements with a single low dose of oral Flupentixol. Further, we examine the potential nosological status of acute onset dyskinesia associated with neuroleptic use.

show abstract